Get the content you want anytime you want.
<< View All Contributors
Saskia v. Popescu, PhD, MPH, MA, CIC, is a hospital epidemiologist and infection preventionist. During her work as an infection preventionist, she performed surveillance for infectious diseases, preparedness, and Ebola-response practices. She holds a doctorate in Biodefense from George Mason University where her research focuses on the role of infection prevention in facilitating global health security efforts. She is certified in Infection Control and has worked in both pediatric and adult acute care facilities.

UV Disinfection Tackles MRSA—What About C Diff?

Health care environments are dirty. There’s no way of avoiding it – hospitals, urgent care facilities, and other medical centers are constantly battling microorganisms. Cleaning and disinfection are critical in these environments to help reduce the risk of transmission. Consider that roughly 1 in 100 people carry methicillin-resistant Staphylococcus aureus (MRSA) while 1 in 3 carry drug-susceptible S aureus in their nose. 

Organisms like MRSA, Candida auris, and Clostridioides difficile, are known to cause diseases in these settings and are often culprits in health care-associated infections. Effectively removing these organisms from the environment is critical for infection control efforts. While disinfecting wipes and sprays have been the go-to for decades, ultraviolet-A (UV-A) light exposure has been growing in popularity. While UV-A is a method for disinfecting surfaces and objects, it can’t sterilize products, but it can help reduce bio-burden in patient rooms, waiting areas, operating rooms, and other high-risk areas. Like many new technologies, UV-A disinfection is still finding its way into hospitals as people become more comfortable with its infection control capabilities.

new study tested the efficacy of UV-A disinfection for decontamination against health care-associated pathogens on surfaces. The researchers used a ceiling light fixture for the UV-A source, testing its efficacy on killing microorganisms by assessing recovery on a version of the American Society for Testing Materials standard quantitative carrier disk test method. This disk includes a strain of MRSA, C diffC auris, and 2 kinds of virus bacteriophages. The efficacy of the UV-A light was also evaluated for its capabilities of reducing contamination of 32 in-use portable pieces medical equipment. Doppler ultrasound machines, glucometers, wheelchairs, and workstations-on-wheels were some of the equipment tested by being placed 2 meters from the light source for 4 hours. 

Researchers found that these 4 hours yielded a significant reduction in pathogenic microorganisms from the medical equipment in use and mostly on the disks. There was a modest reduction in MRSA, C auris, and the bacteriophages, but not C diff spores. “C diff spores were not reduced or minimally reduced after 24 hours of exposure to UV-A at 3 W/m2 (0-0.2 log10 CFU reduction),” the authors wrote.

Prior to the use of the UV-A disinfection of the medical equipment, 37% yielded pathogenic microorganisms, while only 10% did after the disinfection, which was statistically significant.

The authors note that these findings suggest the potential for UV-A disinfection to aid in the reduction of pathogenic microorganisms that contribute to health care-associated infections. There should be a concern though for the health and safety of those exposed, which amplifies the importance of manufacturer guidance and proper protocols. Moreover, this component might increase the required cleaning time for certain areas, which should be considered prior to use.

While the UV-A disinfecting light did provide a modest reduction in microorganisms, the resilience of C diff and the existing microbial burden should not be forgotten. UV-A light has shown promise in its capabilities to reduce microorganisms in health care environments; however, it cannot and should not be a substitute for the manual cleaning and disinfection that is required to remove biofilm and other hardier bioburden. 
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?
More from Saskia v. Popescu
Is there an association with adverse outcomes in patients hospitalized with influenza taking NSAIDS?
PUBLISHED: Mon July 13 2020
How did the Western Pacific Region address rubella in recent outbreaks?
PUBLISHED: Thu July 02 2020
Where did things go wrong for the Grand Canyon State?
PUBLISHED: Thu June 25 2020
A new phase 2b trial shows promise in HCV treatment.
PUBLISHED: Wed June 17 2020